Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

被引：0
|
作者：
Mauro, Michael [1 ]
Paquette, Ronald [2 ]
Hehlmann, Rudiger [3 ]
Williams, Loretta A. [4 ]
Goldberg, Stuart L. [5 ]
Michallet, Mauricette [6 ]
Gambacorti-Passerini, Carlo [7 ]
Tang, Derek [8 ]
DeGutis, Irene S. [8 ]
McBride, Ali [8 ]
Parsons, Lori [9 ]
Montelongo, Monica Z. [9 ]
Cortes, Jorge E. [10 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Heidelberg Univ, Heidelberg, Germany
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[6] Ctr Lutte Canc Leon Berard, Lyon, France
[7] Univ Milano Bicocca, Milan, Italy
[8] Bristol Myers Squibb, Princeton, NJ USA
[9] ICON plc, Blue Bell, PA USA
[10] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163080
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
632
引用
收藏
页码：9624 / 9625
页数：2
相关论文
共 50 条
  • [21] Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
    Jabbour, Elias
    Kantarjian, Hagop M.
    O'Brien, Susan
    Shan, Jianqin
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Rios, Mary Beth
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4260 - 4265
  • [22] VALIDATION OF A PROGNOSTIC SCORING SYSTEM IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER IMATINIB FAILURE
    Boquimpani, C.
    Schaffel, R.
    Graca, D.
    Mesquita, C.
    Peixoto, D.
    Madeira, T.
    Wendling, P.
    Eller, F.
    Biasoli, I.
    Spector, N.
    HAEMATOLOGICA, 2013, 98 : 553 - 553
  • [23] Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
    Yang, Sen
    Zhang, Xiaoshuai
    Gale, Robert Peter
    Du, Xin
    Chen, Chun-yan
    Weng, Jian-yu
    Huang, Jian
    Li, Fei
    Zeng, Yun
    Xiao, Zhen
    Hu, Jian-da
    Yang, Li-jie
    Liu, Zhuo-gang
    Li, Guo-hui
    Sun, Xiu-li
    Yang, Wei
    Feng, Ru
    Han, Yan-qiu
    Jing, Yu
    Xu, Na
    Liu, Xiao-li
    Liu, Zhen-fang
    Wang, Xiao-dong
    Wu, Shi-xin
    Liang, Rong
    Zhang, Yan-li
    Yang, Yun-fan
    Zhu, Huan-ling
    Pan, Ling
    Meng, Li
    Zhao, Yan-hong
    Yi, Hai
    Liu, Yi-lan
    Zhang, Wei-hua
    Zheng, Yuan-jun
    Zhou, Ze-ping
    Chen, Su-ning
    Qiu, Hui-ying
    Li, Wei-ming
    Jia, Zhi-lin
    Bai, Yan-liang
    Lin, Li-e
    Liu, Bing-cheng
    Liu, Chun-shui
    Luo, Jian-min
    Meng, Jun-xia
    Sun, Zhi-qiang
    Zhang, Yan-qing
    Huang, Xiao-jun
    Jiang, Qian
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : E183 - E186
  • [24] First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
    Balsat, Marie
    Alcazer, Vincent
    Etienne, Gabriel
    Huguet, Francoise
    Berger, Marc
    Cayssials, Emilie
    Charbonnier, Aude
    Escoffre-Barbe, Martine
    Johnson-Ansah, Hyacinthe
    Legros, Laurence
    Roy, Lydia
    Delmer, Alain
    Ianotto, Jean-Christophe
    Orvain, Corentin
    Larosa, Fabrice
    Meunier, Mathieu
    Ame, Shanti
    Andreoli, Annalisa
    Cony-Makhoul, Pascale
    Morisset, Stephane
    Tigaud, Isabelle
    Rea, Delphine
    Nicolini, Franck Emmanuel
    LEUKEMIA RESEARCH, 2023, 130
  • [25] Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
    Iurlo, Alessandra
    Orsi, Emanuela
    Cattaneo, Daniele
    Resi, Veronica
    Bucelli, Cristina
    Orofino, Nicola
    Sciume, Mariarita
    Elena, Chiara
    Grancini, Valeria
    Consonni, Dario
    Orlandi, Ester Maria
    Cortelezzi, Agostino
    ONCOTARGET, 2015, 6 (32) : 33944 - 33951
  • [26] Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
    Andreas Hochhaus
    Massimo Breccia
    Giuseppe Saglio
    Valentín García-Gutiérrez
    Delphine Réa
    Jeroen Janssen
    Jane Apperley
    Leukemia, 2020, 34 : 1495 - 1502
  • [27] Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis
    Ke, Liyuan
    Li, Su
    Huang, Danxue
    Wang, Yan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 17 - 26
  • [29] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Abruzzese, Elisabetta
    Breccia, Massimo
    Latagliata, Roberto
    BIODRUGS, 2014, 28 (01) : 17 - 26
  • [30] Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
    Kantarjian, Hagop M.
    Jabbour, Elias
    Deininger, Michael
    Abruzzese, Elisabetta
    Apperley, Jane
    Cortes, Jorge
    Chuah, Charles
    DeAngelo, Daniel J.
    DiPersio, John
    Hochhaus, Andreas
    Lipton, Jeffrey
    Nicolini, Franck E.
    Pinilla-Ibarz, Javier
    Rea, Delphine
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Srivastava, Shouryadeep
    Ren, Xiaowei
    Mauro, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (11) : 1419 - 1426
12345